NCT06560502招募中不适用
A Multicenter, Prospective, Randomized Controlled Modified Multi-Platform (Matriarch) Trial Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Standard of Care Alone in the Management of DFUs and VLUs.
Stability Biologics2 个研究点 分布在 1 个国家目标入组 324 人开始时间: 2024年8月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 324
- 试验地点
- 2
- 主要终点
- Determine the between-arm difference
研究概览
简要总结
This is a multicenter, prospective, randomized controlled modified multi-platform (matriarch) trial evaluating several cellular, acellular, and matrix-like products (CAMPs) and standard of care versus standard of care alone in the management of nonhealing diabetic foot and venous leg ulcers.
详细描述
The purpose of this study is to determine the between-arm difference in the proportion of subjects achieving complete closure of nonhealing diabetic foot ulcers and venous leg ulcers with multiple CAMPs plus SOC versus SOC alone over 12 weeks using a modified dual platform (Matriarch) trial design.
*The initial plan is to evaluate five CAMPs per wound type; however, the modified platform design permits the inclusion of additional CAMPs.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1. Subjects must be at least 21 years of age or older.
- •Subjects must have a diagnosis of type 1 or 2 Diabetes mellitus.
- •At randomization subjects must have a target ulcer with a minimum surface area of 1.0 cm2 and a maximum surface area of 5.0 cm2 measured post debridement .
- •4. The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care, prior to the initial screening visit.
- •5. The target ulcer must be located on the foot with at least 50% of the ulcer below the malleolus.
- •6. The target ulcer must be Wagner 1 or 2 grade, extending at least through the dermis or subcutaneous tissue and may involve the muscle provided it is below the medial aspect of the malleolus.
- •7. The affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:
- •a. ABI between 0.7 and ≤ 1.3; b. TBI ≥ 0.6; c. TCOM ≥ 40 mmHg; d. PVR: biphasic.
- •If the potential subject has two or more ulcers, they must be separated by at least 2 cm post-debridement. The largest ulcer satisfying the inclusion and
排除标准
- •will be designated as the target ulcer.
- •9. Target ulcers located on the plantar aspect of the foot must be offloaded for at least 14 days prior to enrollment.
- •10. The potential subject must consent to using the prescribed offloading method for the duration of the study.
- •11. The potential subject must agree to attend the weekly study visits required by the protocol.
- •12. The potential subject must be willing and able to participate in the informed consent process.
- •Exclusion Criteria:
- •The potential subject is known to have a life expectancy of < 6 months.
- •The potential subject's target ulcer is not secondary to diabetes.
- •The target ulcer is infected, requires systemic antibiotic therapy, or there is cellulitis in the surrounding skin.
- •The target ulcer exposes tendon or bone.
- •There is evidence of osteomyelitis complicating the target ulcer.
- •The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics).
- •The potential subject is taking hydroxyurea .
- •The potential subject has applied topical steroids to the ulcer surface within one month of initial screening.
- •The potential subject with a previous partial amputation on the affected foot that results in a deformity that impedes proper offloading of the target ulcer.
- •The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.
- •The surface area of the target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit ("historical" run-in period). MolecuLight Imaging Device is not required for measurements taken during the historical run-in period (e.g., calculating surface area using length X width is acceptable).
- •The surface area measurement of the Target ulcer decreases by 20% or more during the active 2-week screening phase: the 2 weeks from the initial screening visit (SV-1) to the TV-1 visit during which time the potential subject received SOC.
- •The potential subject has an acute Charcot foot, or an inactive Charcot foot, which impedes proper offloading of the target ulcer.
- •Women who are pregnant or considering becoming pregnant within the next 6 months.
结局指标
主要结局
Determine the between-arm difference
时间窗: 1-12 Weeks
To determine the between-arm difference in the proportion of subjects achieving complete closure of nonhealing diabetic foot ulcers and venous leg ulcers with multiple CAMPs plus SOC versus SOC alone over 12 weeks using a modified dual platform (Matriarch) trial design.
次要结局
- Change in pain in target ulcer(1-12 Weeks)
- Time to closure(1-12 Weeks)
- Percent Area Reduction(1-12 weeks)
- Adverse Events(1-14 weeks)
- Determine improvement in Quality of Life - FWS and determine improvement in Quality of Life - wQOL(1-12 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Non-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-AMNon-infected Diabetic Foot UlcerDiabetic WoundNon-ischemic Diabetic Foot UlcerDiabetic FootDiabetic Foot UlcerNCT06565156BioStem Technologies72
已完成
不适用
A Prospective Trial of Non-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-ACDiabetic Foot UlcerNCT06511596BioStem Technologies71
进行中（未招募）
不适用
GAE Using Embosphere Microspheres vs Corticosteroid Injections for Treatment of Symptomatic Knee OA (MOTION)Knee OsteoarthritisNCT05818150Merit Medical Systems, Inc.264
撤回
不适用
Prospective Randomized International Study on the Reactivation of Burn InjuriesBurnsSkin Graft (Allograft)(Autograft) FailureNCT04951934Emoled
尚未招募
4 期
CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AMLRelapsed/Refractory AMLNCT06763666Nanfang Hospital, Southern Medical University172